MARKET

GTHX

GTHX

G1 Therapeutics Inc
NASDAQ
4.320
-0.150
-3.36%
After Hours: 4.410 +0.09 +2.08% 17:09 03/28 EDT
OPEN
4.490
PREV CLOSE
4.470
HIGH
4.659
LOW
4.300
VOLUME
936.01K
TURNOVER
0
52 WEEK HIGH
5.00
52 WEEK LOW
1.080
MARKET CAP
225.50M
P/E (TTM)
-4.6592
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GTHX last week (0318-0322)?
Weekly Report · 3d ago
G1 Therapeutics Cuts Executive Salaries by 10% Amid Cost-Cutting Measures
G1 Therapeutics said its executive team will see their base salaries reduced by 10%. The company recently extended its cash runway into 2025. The pay cuts will be in place for a two-year period. The oncology company said the cuts will include temporary pay cuts for G1's executives.
Dow Jones · 6d ago
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effects in patients with lung cancer. The company's research pipeline includes exploring new indications for Trilaciclib in breast and bladder cancer. Despite cash burn and dilution concerns, I rate GTHX a speculative "buy" for its promising product pipeline.
Seeking Alpha · 6d ago
G1 Therapeutics Executives Take Pay Cut for Cost Management
TipRanks · 6d ago
Weekly Report: what happened at GTHX last week (0311-0315)?
Weekly Report · 03/18 09:23
Market Sentiment Around Loss-Making G1 Therapeutics, Inc. (NASDAQ:GTHX)
G1 Therapeutics, Inc. Is a commercial-stage biopharmaceutical company. The company posted a loss of US$48m for its most recent financial year. G1Therapeutics is expected to grow 55% year-on-year to breakeven by 2026. Analyst's expect the company to be profitable in 2026, but the company has a high debt-to-equity ratio of 146%. The company is currently valued at US$163m by Simply Wall St.
Simply Wall St · 03/16 13:55
Weekly Report: what happened at GTHX last week (0304-0308)?
Weekly Report · 03/11 09:22
Weekly Report: what happened at GTHX last week (0226-0301)?
Weekly Report · 03/04 09:23
More
About GTHX
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy designed to help and protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lung cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. Its Rintodestrant, is an oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2 (HER2)-breast cancer.

Webull offers G1 Therapeutics Inc stock information, including NASDAQ: GTHX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GTHX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GTHX stock methods without spending real money on the virtual paper trading platform.